Participation in a Research Registry for Immune Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01953016|
Recruitment Status : Recruiting
First Posted : September 30, 2013
Last Update Posted : February 7, 2019
- People with primary immune deficiency diseases (PIDD) have weak immune systems. This makes it hard for their bodies to fight infection. The Immune Deficiency Foundation has a network to collect data about people with PIDD. It is called the United States Immunodeficiency Network. It will help doctors and scientists better understand these disorders. The goal is to get medical data for everyone with these disorders in the U.S. and Canada. Data will be stored in a registry. Researchers can use it to study if these disorders are increasing. They can also learn how the disorders are diagnosed and treated.
- To collect data on people with primary immune deficiency disorders.
- People who have a PIDD.
- Data can be added with no record of personal identity.
- Data can be added with identity kept separate. This data will be linked to the registry by a code number.
- Data for the registry includes:
- Family history
- Disease treatment
- Disease characteristics
- Medical history
- Laboratory data
|Condition or disease|
|Primary Immunodeficiencies APECED CGD (Chronic Granulomatous Disease) Wiskott- Aldrich Syndrome SCID|
The purpose of this protocol is to provide a resource for clinical and laboratory research through enrollment of known immunodeficiency patients into a national registry, the US Immunodeficiency Network (USIDNET). The registry data will expand NIH s and the nation s knowledge base about immune deficiency disorders and genetic mutations that lead to these disorders. Additional registrants from NIH protocols will not only increase the understanding of the molecular basis of these disorders, but also will serve to document and track the incidence and progression of complications.
Objectives and specific aims
The purpose of this proposal is to create a mechanism for depositing NIH data into USIDNET. The patient Registry is designed to obtain longitudinal data on a large number of patients with primary immunodeficiency diseases, and genetic carriers of these defects in order to:
- Learn more about the phenotypic variations seen in a large number of individual patients with the same rare molecular diagnosis.
- Determine the natural history of these genetic disorders of immunity and establish genotype-phenotype correlations.
- Learn effects of various treatment protocols used in these patients over time, including unexpected side effects that may be unique to a particular diagnostic group.
- To evaluate quality of life using standard tools and correlate these with genotype and treatment history.
- To promote collaborative research amongst interested investigators by identifying a larger pool of potential research subjects than would be available at their own institutions
- To identify patients with a specific diagnosis for potential participation in multi-institutional clinical trials designed for diagnosis or therapy or their specific disease.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||NIH Participation to USIDNET Registry|
|Actual Study Start Date :||September 30, 2013|
|Estimated Primary Completion Date :||May 1, 2020|
|Estimated Study Completion Date :||May 1, 2020|
Individual of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
- Prevalence [ Time Frame: Ongoing ]The Registry will provide a minimum estimate of the prevalance of each disorder in US, a comprehensive clinical picture of each disorder, and a resource for clinical and laboratory research.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01953016
|Contact: Elizabeth K Garabedian, R.N.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Elizabeth K Garabedian, R.N.||National Human Genome Research Institute (NHGRI)|